Anterior Segment Nd:YAG Laser Procedures: to Study Intraocular Pressure Spikes and Their Prevention
Abstract
Purpose: To find out quantum of increase in intraocular pressure (IOP) following anterior segment Nd:YAG laser procedures and extent to which this increase is preventable by different groups of antiglaucoma drugs. Methods: Study design: Cross sectional, randomized, double blind analytical study. One hundred and seventy four eyes of 174 patients who underwent anterior segment Nd:YAG laser procedures {peripheral iridotomy (LPI)/ capsulotomy (YLC)}, using energy limited to 50 mJ, were randomized into five groups. Patients in group 1, 2, 3, 4 and 5 received topical Brimonidine tartarate 0.2%, oral Acetazolamide 250mg, topical Dorzolamide hydrochloride 2%, lubricating eye drops plus oral calcium tablets and topical Timolol maleate 0.5% respectively.Patients getting active topical drug were additionally given oral calcium and those getting oral active drug were given topical lubricating drops in a double blind manner. Intraocular pressure was measured at 1, 3, 5 and 24 hours post laser. Results: Rise of IOP from baseline to 1, 3, 5 or 24 hours was not found to be significant in any of the groups receiving ocular hypotensive drug (p>0.05). In the placebo group, the rise of IOP was significant only in one patient at 1, 3 and 5 hours post laser which came down to insignificant
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design. Reported size: 174 participants or records.
Read the paper
Related studies
- Chaos and quantum thermalization
- The Dalton quantum chemistry program system
- Cord Blood Leptin and Adiponectin as Predictors of Adiposity in Children at 3 Years of Age: A Prospective Cohort Study
- Quantitative metabolomics by H-NMR and LC-MS/MS confirms altered metabolic pathways in diabetes
- Stable adiabatic quantum batteries
- A novel self-lipid antigen targets human T cells against CD1c(+) leukemias
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.